CryoLife, Inc. (CRY): Price and Financial Metrics


CryoLife, Inc. (CRY): $17.88

0.25 (+1.42%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CRY POWR Grades


  • Value is the dimension where CRY ranks best; there it ranks ahead of 77.28% of US stocks.
  • CRY's strongest trending metric is Growth; it's been moving down over the last 163 days.
  • CRY's current lowest rank is in the Momentum metric (where it is better than 19.76% of US stocks).

CRY Stock Summary

  • CRY's current price/earnings ratio is 383.51, which is higher than 98.41% of US stocks with positive earnings.
  • Price to trailing twelve month operating cash flow for CRY is currently 322.65, higher than 98.98% of US stocks with positive operating cash flow.
  • Over the past twelve months, CRY has reported earnings growth of 26,492.96%, putting it ahead of 99.83% of US stocks in our set.
  • Stocks that are quantitatively similar to CRY, based on their financial statements, market capitalization, and price volatility, are MDWT, APO, WBA, ROYL, and VG.
  • CRY's SEC filings can be seen here. And to visit Cryolife Inc's official web site, go to www.cryolife.com.

CRY Valuation Summary

  • In comparison to the median Healthcare stock, CRY's price/sales ratio is 2.63% lower, now standing at 3.7.
  • CRY's EV/EBIT ratio has moved up 129.6 over the prior 243 months.
  • Over the past 243 months, CRY's price/sales ratio has gone down 4.3.

Below are key valuation metrics over time for CRY.

Stock Date P/S P/B P/E EV/EBIT
CRY 2021-08-31 3.7 3.4 -88.6 176.5
CRY 2021-08-30 3.6 3.4 -86.9 173.9
CRY 2021-08-27 3.6 3.4 -87.6 175.0
CRY 2021-08-26 3.5 3.2 -84.1 169.5
CRY 2021-08-25 3.6 3.3 -85.8 172.3
CRY 2021-08-24 3.6 3.4 -87.4 174.7

CRY Growth Metrics

    Its 2 year net cashflow from operations growth rate is now at 719.44%.
  • Its 5 year cash and equivalents growth rate is now at 41.39%.
  • Its year over year cash and equivalents growth rate is now at -10.78%.
CRY's revenue has moved up $24,497,000 over the prior 33 months.

The table below shows CRY's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 287.338 2.149 1.808
2021-06-30 280.262 12.737 -11.644
2021-03-31 257.885 6.695 -13.155
2020-12-31 253.227 12.369 -16.682
2020-09-30 255.028 7.979 -13.905
2020-06-30 257.778 13.16 -11.169

CRY's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CRY has a Quality Grade of D, ranking ahead of 18.67% of graded US stocks.
  • CRY's asset turnover comes in at 0.353 -- ranking 123rd of 186 Medical Equipment stocks.
  • CSII, BIOL, and NVRO are the stocks whose asset turnover ratios are most correlated with CRY.

The table below shows CRY's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.353 0.664 0.014
2021-03-31 0.337 0.665 0.007
2020-12-31 0.351 0.663 -0.001
2020-09-30 0.378 0.666 0.000
2020-06-30 0.410 0.667 0.004
2020-03-31 0.455 0.665 0.022

CRY Price Target

For more insight on analysts targets of CRY, see our CRY price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $34.19 Average Broker Recommendation 1.38 (Strong Buy)

CRY Stock Price Chart Interactive Chart >

Price chart for CRY

CRY Price/Volume Stats

Current price $17.88 52-week high $32.34
Prev. close $17.63 52-week low $16.95
Day low $17.49 Volume 257,400
Day high $18.22 Avg. volume 198,221
50-day MA $19.29 Dividend yield N/A
200-day MA $24.09 Market Cap 703.22M

CryoLife, Inc. (CRY) Company Bio


CryoLife Inc. engages in the manufacturing, processing, and distribution of implantable living tissues and medical devices used in cardiac and vascular surgical procedures. The company was founded in 1984 and is based in Kennesaw, Georgia.


CRY Latest News Stream


Event/Time News Detail
Loading, please wait...

CRY Latest Social Stream


Loading social stream, please wait...

View Full CRY Social Stream

Latest CRY News From Around the Web

Below are the latest news stories about Cryolife Inc that investors may wish to consider to help them evaluate CRY as an investment opportunity.

CryoLife Announces Corporate Rebranding and Changes Name to Artivion

CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it was renaming and rebranding itself to Artivion, Inc., effective immediately. Derived from the words "aorta", "innovation", and "vision", the company's new name and brand reflect its evolution to focus on providing innovative technologies to surgeons who treat patients with aortic disease. In conjunction with these changes, effective January 24, 2022, the company will also

Yahoo | January 18, 2022

CryoLife (CRY) Investor Presentation (Slideshow)

The following slide deck was published by CryoLife, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | January 14, 2022

Are CryoLife, Inc.'s (NYSE:CRY) Mixed Financials Driving The Negative Sentiment?

It is hard to get excited after looking at CryoLife's (NYSE:CRY) recent performance, when its stock has declined 13...

Yahoo | December 27, 2021

CryoLife to Participate in the Canaccord Genuity Virtual MedTech, Diagnostics, and Digital Health & Services Forum

CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that members of management will host one-on-one meetings at the upcoming Canaccord Genuity MedTech, Diagnostics, and Digital Health & Services Forum on Thursday, November 18, 2021. Due to the format of this event no webcast will be available.

Yahoo | November 9, 2021

Wall Street Analysts Think CryoLife (CRY) Could Surge 51%: Read This Before Placing a Bet

The mean of analysts' price targets for CryoLife (CRY) points to a 50.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Yahoo | November 8, 2021

Read More 'CRY' Stories Here

CRY Price Returns

1-mo N/A
3-mo N/A
6-mo -16.14%
1-year N/A
3-year -41.34%
5-year -9.24%
YTD -12.14%
2021 -13.81%
2020 -12.85%
2019 -4.55%
2018 48.20%
2017 0.00%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6146 seconds.